BUDGET IMPACT EVALUATION OF A PNEUMOCOCCAL CONJUGATED VACCINE (PCV) 13 VALENT VACCINATION WITH FREE CAMPAIGN PROGRAM FOR CORPORATIONS VESUS NO VACCINATION FOR OLDER ADULTS

被引：0
|
作者：
Fujii, R. K. [1 ]
Presa, J. [1 ]
Roberts, C. S. [2 ]
Gea, Y. [1 ]
Manfrin, D. F. [1 ]
Mould, J. [2 ]
机构：
[1] Pfizer Inc, Sao Paulo, Brazil
[2] Pfizer, New York, NY USA
来源：
VALUE IN HEALTH | 2013年 / 16卷 / 03期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A84 / A84
页数：1
相关论文
共 50 条
  • [11] ECONOMIC IMPACT OF 13-VALENT PNEUMOCOCCAL CONJUGATE VACCINE (PCV13) VERSUS NO VACCINATION IN ADULTS >60 YEARS, IN COSTA RICAN SOCIAL SECURITY
    Chaverri, J.
    Castro, J.
    VALUE IN HEALTH, 2020, 23 : S171 - S171
  • [12] A cost-effectiveness analysis of vaccinating older adults with the 23-valent pneumococcal polysaccharide vaccine (PPV23) compared to no vaccination, the 13-valent pneumococcal conjugate vaccine (PCV13), or PCV13 followed by PPV23 in Colombia
    Prieto, E.
    Jiang, Y.
    Yang, X.
    Graham, J. B.
    Monsanto, H.
    Ruiz, J.
    Beltran, C.
    Rojas, M.
    INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2018, 73 : 13 - 13
  • [13] COST-EFFECTIVENESS OF 13-VALENT VERSUS 23-VALENT PNEUMOCOCCAL POLYSACCHARIDE VACCINE AND NO VACCINATION IN THE CZECH NATIONAL VACCINATION PROGRAM
    Zigmond, J.
    Tichopad, A.
    Kolek, V
    Roberts, C. S.
    Hajek, P.
    VALUE IN HEALTH, 2013, 16 (03) : A73 - A74
  • [14] Evaluation of appropriateness of vaccination procedures of the 13-valent pneumococcal conjugate vaccine and the 23-valent pneumococcal polysaccharide vaccine in a hospital setting
    Coleman, Paige
    Sears, Matthew
    Vaichys, Sabina
    Nemecek, Branden
    Guarascio, Anthony
    PHARMACOTHERAPY, 2015, 35 (11): : E305 - E305
  • [15] Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine administered to older infants and children naive to pneumococcal vaccination
    Wysocki, Jacek
    Brzostek, Jerzy
    Szymanski, Henryk
    Tetiurka, Boguslaw
    Toporowska-Kowalska, Ewa
    Wasowska-Krolikowska, Krystyna
    Sarkozy, Denise A.
    Giardina, Peter C.
    Gruber, William C.
    Emini, Emilio A.
    Scott, Daniel A.
    VACCINE, 2015, 33 (14) : 1719 - 1725
  • [16] THE COST-EFFECTIVENESS OF THE NEW PNEUMOCOCCAL 13-VALENT CONJUGATE VACCINE (PCV13) FOR CHILDHOOD AND ADULT VACCINATION IN THE UK
    Patel, R.
    Stoykova, B.
    Lloyd, A. C.
    Willingham, J.
    Hollingsworth, R.
    VALUE IN HEALTH, 2009, 12 (07) : A427 - A427
  • [17] Cost effectiveness of pneumococcal vaccination among Dutch infants: an economic analysis of the seven valent pneumococcal conjugated vaccine and forecast for the 10 valent and 13 valent vaccines
    Rozenbaum, Mark H.
    Sanders, Elisabeth A. M.
    van Hoek, Albert Jan
    Jansen, Angelique G. S. C.
    van der Ende, Arie
    van den Dobbelsteen, Germie
    Rodenburg, Gerwin D.
    Hak, Eelko
    Postma, Maarten J.
    BMJ-BRITISH MEDICAL JOURNAL, 2010, 340 : 1347
  • [18] EVALUATION OF IMMUNE RESPONSE TO 13-VALENT PNEUMOCOCCAL CONJUGATED VACCINE (PCV13) IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKAEMIA
    Pasiarski, M.
    Stelmach-Goldys, A.
    Gozdz, S.
    Grywalska, E.
    Hus, I.
    Rolinski, J.
    HAEMATOLOGICA, 2014, 99 : 322 - 322
  • [19] Impact of the national routine vaccination program on 23-valent pneumococcal polysaccharide vaccine vaccination rates in elderly persons in Japan
    Naito, Toshio
    Yokokawa, Hirohide
    Watanabe, Akira
    JOURNAL OF INFECTION AND CHEMOTHERAPY, 2018, 24 (06) : 496 - 498
  • [20] Cost effectiveness of adding 7-valent pneumococcal conjugate (PCV-7) vaccine to the Norwegian childhood vaccination program
    Wisloff, Torbjorn
    Abrahamsen, Tore G.
    Riise Bergsaker, Marianne A.
    Lovoll, Oistein
    Moller, Per
    Pedersen, Maren Kristine
    Kristiansen, Ivar Sonbo
    VACCINE, 2006, 24 (29-30) : 5690 - 5699
12345